Resonance Health (RHT.AX) Akcija Cena
Resonance Health Cena
Ieņēmumi auga par 11,9 % gadā pēdējos 19 gados līdz 15,75 M AUD. Peļņa uz akciju auga par 3,8 % gadā pēdējos 17 gados. Resonance Health neto marža tagad ir 9,6 %, pieaugusi no -29,8 % pirms dažiem gadiem.
Resonance Health akcijas cena
Iegūstiet šos datus caur Eulerpool API
100 000 pieprasījumu/mēn. bez maksas · bez kartes
Resonance Health biznesa modelis un akciju analīze
Bieži uzdotie jautājumi par Resonance Health akciju
The business model of Resonance Health Ltd focuses on providing innovative medical imaging software and services. The company aims to improve patient care and outcomes through its advanced technology solutions. Resonance Health specializes in the development and commercialization of non-invasive diagnostic tools, particularly in the field of liver and cardiac diseases. By leveraging its expertise in quantitative analysis and iron overload assessment, Resonance Health offers reliable and efficient solutions for diagnosing and managing various health conditions. The company operates by licensing its software to medical institutions and partnering with healthcare providers, ensuring widespread accessibility and utilization of its cutting-edge technologies.
Resonance Health Ltd is primarily active in the healthcare and medical technology industries.
The main competitors of Resonance Health Ltd in the market include other companies operating in the medical diagnostics and healthcare sector. Some prominent competitors are InHealth Group, Q BioMed, and Novartis AG. Resonance Health Ltd faces competition from these companies in developing innovative diagnostic solutions and providing high-quality healthcare services.
Resonance Health Ltd. is a leading provider of automated, non-invasive medical imaging software and analysis services. Founded in 1987, the company has a rich history of innovation and expertise in the field of liver and cardiac MRI imaging. Resonance Health's technology allows for accurate and reliable diagnosis of liver iron concentration and cardiac ejection fraction, essential measurements for monitoring patients with iron overload and heart conditions. With a strong commitment to research and development, Resonance Health continues to develop cutting-edge solutions that improve patient outcomes and streamline healthcare processes. As a trusted name in the industry, Resonance Health Ltd. has gained recognition globally for its advanced medical imaging products and services.
Resonance Health Ltd, a leading company in the healthcare sector, has accomplished several significant milestones. One noteworthy achievement is the development of FerriScan®, an advanced diagnostic tool for measuring liver iron concentration. Through extensive research and innovative technology, Resonance Health Ltd has revolutionized the diagnosis and monitoring of iron overload disorders such as hereditary hemochromatosis and thalassemia. The company has also expanded its global presence by establishing partnerships with renowned medical institutions and securing regulatory approvals for its groundbreaking products. With a relentless commitment to advancing patient care, Resonance Health Ltd continues to make remarkable strides in the field of medical diagnostics.
Resonance Health Ltd is primarily present in multiple countries and regions across the world. With its global reach, the company has established a strong presence in key markets. Its operations span across Australia, the United States, Europe, and Asia-Pacific regions. Resonance Health Ltd's commitment to expanding its footprint internationally has enabled it to serve a diverse range of customers and collaborate with partners on a global scale. This global presence reinforces Resonance Health Ltd's position as a leading player in the industry while allowing it to leverage various market opportunities and better serve its stakeholders.
Resonance Health Ltd represents values of innovation, excellence, and integrity in its corporate philosophy. As a leading stock health company, Resonance Health Ltd focuses on utilizing advanced technology and research to improve the diagnosis and treatment of liver diseases and iron disorders. With a dedicated team of experts, the company prioritizes accuracy and efficiency in its solutions, delivering reliable results to healthcare professionals worldwide. Resonance Health Ltd strives to enhance patient care by providing precise diagnostic tools, earning recognition for its commitment to quality and advancing medical knowledge.
Pēc pašreizējā kursa Resonance Health akcija maksā 0,05 EUR (0,07 AUD).
Resonance Health akcija (RHT.AX) tiek kotēta 1 biržās, tostarp: ASX (RHT.AX).
Resonance Health Ltd is a medical technology and software company specializing in the development and marketing of medical imaging devices, software, and services. The company is based in Perth, Australia, and operates worldwide.
apgrozījums Resonance Health ir 15,75 M AUD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.
peļņa Resonance Health ir 1,51 M AUD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.
Resonance Health cenas un peļņas rādītājs (P/E) pašlaik ir 23,30. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Resonance Health akcijas vērtību.
Resonance Health cenas un apgrozījuma rādītājs (P/S) pašlaik ir 2,24. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Resonance Health akcijas vērtības mērs.
Resonance Health Eulerpool kvalitātes rādītājs ir 6/10.
Resonance Health ISIN ir AU000000RHT2. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.
Resonance Health WKN ir A0BK8V. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.
Resonance Health tikeris ir RHT.AX. Tikeris tiek izmantots Resonance Health akciju tirdzniecībai biržā.
Resonance Health akcija
Resonance Health Salīdzināmo uzņēmumu grupa
Resonance Health Biržas kods
Resonance Health FIGI
Visi Resonance Health fundamentālie rādītāji un padziļinātā analīze
Mūsu akciju analīze par Resonance Health ietver svarīgus finanšu rādītājus, piemēram, apgrozījumu, peļņu, P/E rādītāju, P/S rādītāju, EBIT, kā arī informāciju par dividendēm. Turklāt mēs aplūkojam aspektus kā akcijas, tirgus kapitalizāciju, parādus, pašu kapitālu un saistības no Resonance Health. Ja meklējat sīkāku informāciju par šīm tēmām, piedāvājam detalizētas analīzes mūsu apakšlapās: